WHO recommends Merck COVID-19 pill for non-severe, at-risk patients | Inquirer News

WHO recommends Merck COVID-19 pill for non-severe, at-risk patients

/ 04:53 PM March 03, 2022

Thailand and Indonesia unveil plans to develop molnupiravir COVID-19 pill

 An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via REUTERS

PARIS — The World Health Organization on Wednesday recommended an anti-Covid pill be taken by sufferers who have mild symptoms but are at high risk of hospitalization, such as older people or the unvaccinated.

The pill, called molnupiravir and developed by US pharmaceutical Merck, is taken as soon as possible after Covid-19 symptoms develop and then for the following five days.


A WHO group of experts said in the British Medical Journal that people with weak immune systems or chronic disease were also recommended to take the pill if they had non-severe Covid.


However “young and healthy patients, including children, and pregnant and breastfeeding women should not be given the drug due to potential harms,” they said.

The UN agency’s new recommendation was based on the results of six randomized controlled trials involving 4,796 patients, the “largest dataset on this drug so far”.

The trials suggested that molnupiravir reduced the risk of going to hospital, with 43 fewer admissions per 1,000 high-risk patients, as well as speeding up the pace at which symptoms cleared up by an average of 3.4 days.

There was less indication it had an affect on mortality, with just six fewer deaths per 1,000 patients.

The WHO acknowledged “that cost and availability issues associated with molnupiravir may make access to low- and middle-income countries challenging and exacerbate health inequity”.

While vaccines remain the foremost tools in the fight against the pandemic, experts have welcomed the addition of the new oral treatments, which inhibit the virus’ ability to replicate and should withstand variants.


The only other main anti-Covid pill available is Pfizer’s Paxlovid.

However more potential concerns have been raised about Merck’s pill, which the US Food and Drug Administration has not authorised for under-18s because it could affect bone and cartilage growth.


Merck’s COVID-19 pill significantly less effective in new analysis

US FDA panel recommends agency authorize Merck’s COVID-19 drug

Indonesia approves Merck’s COVID-19 pill for emergency use

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Explainer: How does Merck’s COVID-19 pill compare to Pfizer’s?

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, Health, Merck, WHO

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.